Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jalaj Garg

Clinical Cardiac Electrophysiology Loma Linda, CA Medical Doctor

NPI 1558631663 CMS profile 1384266

11234 Anderson St, Loma Linda, CA 92354

Open in the dashboard

General payments

$88,520

367 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jalaj Garg of Loma Linda, CA is reported in the CMS Open Payments database as having received $88,520 across 367 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,205 74
2024 General $15,698 60
2023 General $34,265 98
2022 General $23,282 67
2021 General $3,277 33
2019 General $1,794 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jalaj Garg
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Jalaj Garg were reported at $10,205. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Jalaj Garg Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,794 $2,361 $585–$8,260 $163
2020 $0 $993 $247–$4,351 $114
2021 $3,277 $1,185 $326–$4,739 $132
2022 $23,282 $2,073 $554–$6,789 $149
2023 $34,265 $2,568 $759–$8,159 $160
2024 $15,698 $2,557 $703–$7,403 $164
2025 $10,205 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $23,739 93 payments
  2. Atricure, Inc. $18,571 28 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $8,740 13 payments
  4. Medical Device Business Services, Inc. $8,550 6 payments
  5. Biosense Webster, Inc. $7,257 81 payments
  6. Biotronik Inc. $6,918 37 payments
  7. AltaThera Pharmaceuticals LLC $5,551 7 payments
  8. Abbott Laboratories $3,200 30 payments
  9. Kestra Medical Technology Services, Inc. $2,675 8 payments
  10. Boston Scientific Corporation $1,774 45 payments
  11. Other $1,545 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $24,475 16 payments
  2. Travel and Lodging $22,516 49 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,748 8 payments
  4. Food and Beverage $10,655 283 payments
  5. Honoraria $8,589 6 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $2,000 1 payment
  7. Education $537 4 payments
Products named General payments · program years 2019–2025
  1. SYNERGY ABLATION SYSTEM $16,682 19 payments
  2. Carto 3 $13,942 66 payments
  3. Micra $9,430 51 payments
  4. ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2) $9,368 5 payments
  5. LifeVest $8,740 13 payments
  6. Sotalol Hydrochloride $5,551 7 payments
  7. Assure WCD $2,607 7 payments
  8. EnSite Precision Cardiac Mapping System $1,744 11 payments
  9. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $1,430 9 payments
  10. Solia $1,270 4 payments
  11. Other $11,470 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

873

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$379,885

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

40%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 290 $315,244
Xarelto Rivaroxaban Brand 31 $45,535
Farxiga Dapagliflozin Propanediol Brand 12 $11,956
Metoprolol Succinate Generic 220 $3,251
Flecainide Acetate Generic 40 $1,097
Amiodarone Hcl Generic 74 $1,030
Atorvastatin Calcium Generic 24 $497
Metoprolol Tartrate Generic 58 $351
Amlodipine Besylate Generic 22 $235
Lisinopril Generic 12 $124

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$197,826

Medicare's payments for the services billed

Medicare patients

495

Average age 76

Services billed

1,767

256 women, 239 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 74%
Heart failure 64%
Arthritis 52%
Ischemic heart disease 51%
Diabetes 49%
Chronic kidney disease 44%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sotalol Hydrochloride
  • AltaThera Pharmaceuticals LLC $600
$600 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $592
$592 31 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

367 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record